Clinical Trial: Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC

U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07244016) titled 'Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC' on May 08.

Brief Summary: This is a prospective observational clinical study designed to predict the therapeutic efficacy of first-line treatment with tislelizumab combined with standard chemotherapy in patients with ES-SCLC using TCR repertoire technology. The study plans to enroll 40 treatment-naive patients with ES-SCLC.

Study Start Date: Feb. 20

Study Type: OBSERVATIONAL

Condition: Extensive-stage Small-cell Lung Cancer

Recruitment Status: RECRUITING

Sponsor: Henan Cancer Hospital

Disclaimer: Curated by...